Liraglutide prevents diabetes progression in prediabetic OLETF rats

Endocrine Journal

Volumn 60, Issue 1, 2013, Pages 15-28

  Guo, Nanjing ^a,b   Sun, Jia ^a   Chen, Hong ^a   Zhang, Hua ^a   Zhang, Zhen ^a   Cai, Dehong ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

Apoptotic factors; Inflammatory markers; Otsuka long evans tokushima fatty (OLETF) rat; Pancreatic transcription factors; Prediabetic

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; GLUCOSE; INSULIN; INTERLEUKIN 6; LIRAGLUTIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BAX; PROTEIN BCL 2; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATORY CELL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; NONHUMAN; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PANCREAS ISLET CELL FUNCTION; PANCREAS ISLET CELL HYPERPLASIA; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; SCAR FORMATION; UPREGULATION;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; EATING; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; PREDIABETIC STATE; RATS; RATS, INBRED OLETF;

EID: 84873513176     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ12-0094     Document Type: Article

References (43)

1. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A et al. (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26(11):3160-3167.
2. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Geiss LS, Gregg EW (2006) Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 29(6):1263-1268.
3. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q et al. (2010) Prevalence of diabetes among men and women in China. N Engl J Med 362(12):1090-1101.
4. Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414(6865):782-787.
5. Nichols GA, Hillier TA, Brown JB (2007) Progression from newly acquired impaired fasting glusose to type 2 diabetes. Diabetes Care 30(2):228-233.
6. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, Cameron AJ, Dwyer T, Taylor HR, Tonkin AM et al. (2007) Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 116(2):151-157.
7. Thompson AM, Zhang Y, Tong W, Xu T, Chen J, Zhao L, Kelly TN, Chen CS, Bazzano LA, He J (2011) Association of inflammation and endothelial dysfunction with metabolic syndrome, prediabetes and diabetes in adults from Inner Mongolia, China. BMC Endocr Disord 11:16.
8. Ning F, Tuomilehto J, Pyorala K, Onat A, Soderberg S, Qiao Q (2010) Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Diabetes Care 33(10):2211-2216.
9. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB et al. (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20(4):537-544.
10. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344(18):1343-1350.
11. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM (2009) 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374(9702):1677-1686.
12. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6):393-403.
13. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B (2004) Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53(3):654-662.
14. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, During M, Matthews DR (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32(1):84-90.
15. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373(9662):473-481.
16. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374(9683):39-47.
17. Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, Trautmann M (2010) Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 33(6):1173-1175.
18. Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374(9701):1606-1616.
19. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rossner S et al. (2012) Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 36: 843-854.
20. Cummings BP, Stanhope KL, Graham JL, Baskin DG, Griffen SC, Nilsson C, Sams A, Knudsen LB, Raun K, Havel PJ (2010) Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats. Diabetes 59(10):2653-2661.
21. Appleton DJ, Rand JS, Sunvold GD (2005) Basal plasma insulin and homeostasis model assessment (HOMA) are indicators of insulin sensitivity in cats. J Feline Med Surg 7(3):183-193.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412-419.
23. Wolever TM, Jenkins DJ (1986) The use of the glycemic index in predicting the blood glucose response to mixed meals. Am J Clin Nutr 43(1):167-172.
24. Shima K, Shi K, Sano T, Iwami T, Mizuno A, Noma Y (1993) Is exercise training effective in preventing diabetes mellitus in the Otsuka-Long-Evans-Tokushima fatty rat, a model of spontaneous non-insulin-dependent diabetes mellitus? Metabolism 42(8):971-977.
25. Services USDoHaH, Administration FaD (2005) Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. http://fdadrugs.legalview.com/legal-issue/allay/fda-alerts/guidance-for-industry-estimating-the-maximum-safe-starting-dose-inini/449452/.
26. Kawano K, Hirashima T, Mori S, Natori T (1994) OLETF (Otsuka Long-Evans Tokushima Fatty) rat: a new NIDDM rat strain. Diabetes Res Clin Pract 24 Suppl:S317-320.
27. Chen D, Wang MW (2005) Development and application of rodent models for type 2 diabetes. Diabetes Obes Metab 7(4):307-317.
28. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T (1992) Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 41(11):1422-1428.
29. Arya R, Duggirala R, Jenkinson CP, Almasy L, Blangero J, O'Connell P, Stern MP (2004) Evidence of a novel quantitative-trait locus for obesity on chromosome 4p in Mexican Americans. Am J Hum Genet 74(2):272-282.
30. Mochizuki K, Fukaya N, Tanaka Y, Fuchigami M, Goda T (2011) Treatment with the alpha-glucosidase inhibitor miglitol from the preonset stage in Otsuka Long-Evans Tokushima Fatty rats improves glycemic control and reduces the expression of inflammatory cytokine genes in peripheral leukocytes. Metabolism 60(11):1560-1565.
31. Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA, Roan JL, Vu C, Laugero KD, Parkes DG et al. (2006) Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 30(9):1332-1340.
32. Sturis J, Gotfredsen CF, Romer J, Rolin B, Ribel U, Brand CL, Wilken M, Wassermann K, Deacon CF, Carr RD et al. (2003) GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 140(1):123-132.
33. Wang Q, Brubaker PL (2002) Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/ db mice. Diabetologia 45(9):1263-1273.
34. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286(3):327-334.
35. Festa A, D'Agostino R, Jr., Tracy RP, Haffner SM (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51(4):1131-1137.
36. Hasnan J, Yusof MI, Damitri TD, Faridah AR, Adenan AS, Norbaini TH (2010) Relationship between apoptotic markers (Bax and Bcl-2) and biochemical markers in type 2 diabetes mellitus. Singapore Med J 51(1):50-55.
37. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Sondergaard RE, Davies M (2010) Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375(9724):1447-1456.
38. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444(7121):840-846.
39. Man ZW, Zhu M, Noma Y, Toide K, Sato T, Asahi Y, Hirashima T, Mori S, Kawano K, Mizuno A et al. (1997) Impaired beta-cell function and deposition of fat droplets in the pancreas as a consequence of hypertriglyceridemia in OLETF rat, a model of spontaneous NIDDM. Diabetes 46(11):1718-1724.
40. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB (2007) Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 56(1):8-15.
41. Hattori Y, Jojima T, Tomizawa A, Satoh H, Hattori S, Kasai K, Hayashi T (2010) A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 53(10):2256-2263.
42. Irie S, Matsumura Y, Zdravkovic M, Jacobsen LV, Kageyama S (2008) Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study. Int J Clin Pharmacol Ther 46(6):273-279.
43. Drucker DJ (2003) Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26(10):2929-2940.